<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979758</url>
  </required_header>
  <id_info>
    <org_study_id>Fuwai Hospital 2009</org_study_id>
    <nct_id>NCT00979758</nct_id>
  </id_info>
  <brief_title>Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction</brief_title>
  <acronym>STEM-AMI</acronym>
  <official_title>Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of current stem cell transplantation therapy for myocardial infarction is limited
      by low survival rate for stem cell. The purpose of this study is to test whether intensive
      Atorvastatin therapy can improve the outcome of patients with impaired left ventricle
      function after myocardial infarction who underwent intracoronary transfer of autologous bone
      marrow cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major challenge to a successful stem cell therapy for myocardial infarction is the low
      survival rate of implanted cells in the damaged tissue. Atorvastatin, an HMG-CoA reductase
      inhibitor, has multiple biological activities independent of cholesterol-lowering action.This
      study is performed to find out more information about the strategy with Atorvastatin therapy
      to improve the survival of implanted cells. autologous bone marrow stem cells
      transplantation. Patients between 30 and 80 years of age who receive autologous bone marrow
      stem cell transplant at the Fuwai cardiovascular hospital may be eligible for this study.
      These patients receive autologous bone marrow cells transplantation intracoronary undergoing
      Percutaneous Coronary Intervention with regular or high dose of Atorvastatin treatment. The
      objective evaluations will be performed at baseline and during 12 months follow-up.

      Heart function tests may include the following:

        1. Electrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes
           placed on the chest transmit information from the heart to a machine.

        2. Echocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of
           the heart and examine the function of the heart chambers and valves.

        3. Gated acquisition scan is a nuclear medicine test that uses a small amount of
           radioactive chemical injected into a vein. A special scanner creates an image of the
           heart for examining the beating motion of the muscle.

        4. MRI evaluates function of the heart chambers the beating motion of the muscle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction from baseline to 12 months' follow-up</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Stem Cell Transplantation</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Atorvastatin routine dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin Intensive dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin+Transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin routine dose+ Mononuclear cells Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Atorvastatin+Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin intensive dose+ Mononuclear cells Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin and mononuclear cells transplantation</intervention_name>
    <description>Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Intensive Atorvastatin</arm_group_label>
    <arm_group_label>Atorvastatin+Transplantation</arm_group_label>
    <arm_group_label>Intensive Atorvastatin+Transplantation</arm_group_label>
    <other_name>Statin</other_name>
    <other_name>Bone marrow stem cells transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with coronary disease undergoing PCI.

          2. At most 2 months since last episode of ST-elevation myocardial infarction.

          3. Left ventricular ejection fraction &gt;=20% &lt;=45% based on coronary angiography or
             echocardiography.

        Exclusion Criteria:

        Any one of the following exclusion criteria is sufficient to disqualify a patient from the
        study.

          1. Patients with non-ST-elevation myocardial infarction.

          2. Patients with normal left ventricular function.

          3. Patients with mechanical complications of myocardial infarction.

          4. Patients with a malignant tumor.

          5. Patients with infection disease.

          6. Less than 6 months since last episode of stroke.

          7. Patients with hematological disease (leukemia, myeloproliferative disease, or
             myelodysplastic syndromes).

          8. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.

          9. Leukocytes less than 4,000/µL or exceeding 10,000/µL.

         10. Platelets less than 100,000/µL.

         11. Hemoglobin less than 10 g/dL.

         12. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming
             pregnant before the end of the study period.

         13. Any other reason that the Clinical Supervisors or Clinical Researchers may have for
             considering a case unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang yuejin, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yuejin Yang</investigator_full_name>
    <investigator_title>Vice president of Fuwai hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

